That does appear to be the case, WBA. Does the fact that it's a 'De Novo' request that has been 'cleared' by the FDA, mean something different to a full FDA 'Approval' of a new drug? There seems to be totally different language being used than is/has been for SB. And it seems (from this link - https://www.rimsys.io/blog/de-novo-classification-process-a-beginners-guide) that competitors will be able to copy suite straight away and develop a like product. Unlike SB. I wonder what it's priced at. But, it does look like more competition.
BOT - Anything but charting, page-4580
-
- There are more pages in this discussion • 4,691 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.055(16.9%) |
Mkt cap ! $687.8M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 38.0¢ | 33.0¢ | $7.103M | 19.63M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 134000 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 650314 | 19 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |